{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:27:28Z","timestamp":1767338848965,"version":"3.28.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,24]]},"DOI":"10.7759\/cureus.72306","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T16:11:18Z","timestamp":1729786278000},"source":"Crossref","is-referenced-by-count":1,"title":["\"Pardon My Language\": The Curious Case of a Bloody Sandwich and the John Cunningham Virus Reactivation in the Era of Immunomodulatory Drugs"],"prefix":"10.7759","author":[{"given":"Francis","family":"Guerra-Bauman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica  E","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asfandyar","family":"Latif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Cohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Assalita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Progressive Multifocal Leukoencephalopathy","author":"Saji AM","year":"2024","unstructured":"Saji AM, Gupta V. Progressive Multifocal Leukoencephalopathy. StatPearls, Treasure Island, FL; 2024."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese I","year":"2021","unstructured":"Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021, 17:37-51. 10.1038\/s41582-020-00427-y","journal-title":"Nat Rev Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.4.1137-1138.1998","article-title":"Detection of JC virus in cerebrospinal fluid (CSF) samples from patients with progressive multifocal leukoencephalopathy but not in CSF samples from patients with herpes simplex encephalitis, enteroviral meningitis, or multiple sclerosis","volume":"36","author":"Bogdanovic G","year":"1998","unstructured":"Bogdanovic G, Priftakis P, Hammarin AL, S\u00f6derstr\u00f6m M, Samuelson A, Lewensohn-Fuchs I, Dalianis T. Detection of JC virus in cerebrospinal fluid (CSF) samples from patients with progressive multifocal leukoencephalopathy but not in CSF samples from patients with herpes simplex encephalitis, enteroviral meningitis, or multiple sclerosis. J Clin Microbiol. 1998, 36:1137-8. 10.1128\/JCM.36.4.1137-1138.1998","journal-title":"J Clin Microbiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy030","article-title":"Diagnostic and prognostic value of JC virus DNA in plasma in progressive multifocal leukoencephalopathy","volume":"67","author":"Ferretti F","year":"2018","unstructured":"Ferretti F, Bestetti A, Yiannoutsos CT, et al.. Diagnostic and prognostic value of JC virus DNA in plasma in progressive multifocal leukoencephalopathy. Clin Infect Dis. 2018, 67:65-72. 10.1093\/cid\/ciy030","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger JR","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, et al.. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013, 80:1430-8. 10.1212\/WNL.0b013e31828c2fa1","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar SV","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022, 97:1086-107. 10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04294-x","article-title":"Progressive multifocal leukoencephalopathy in multiple myeloma. A literature review and lessons to learn","volume":"100","author":"Koutsavlis I","year":"2021","unstructured":"Koutsavlis I. Progressive multifocal leukoencephalopathy in multiple myeloma. A literature review and lessons to learn. Ann Hematol. 2021, 100:1-10. 10.1007\/s00277-020-04294-x","journal-title":"Ann Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1098930","article-title":"Progressive multifocal leukoencephalopathy in a patient with multiple myeloma: a case report and analysis of the FDA adverse event reporting system","volume":"14","author":"Jonasson E","year":"2023","unstructured":"Jonasson E, Antulov R, Tr\u00f8llund Pedersen P, Sejb\u00e6k T. Progressive multifocal leukoencephalopathy in a patient with multiple myeloma: a case report and analysis of the FDA adverse event reporting system. Front Neurol. 2023, 14:1098930. 10.3389\/fneur.2023.1098930","journal-title":"Front Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1756285615602832","article-title":"Progressive multifocal leukoencephalopathy: current treatment options and future perspectives","volume":"8","author":"Pavlovic D","year":"2015","unstructured":"Pavlovic D, Patera AC, Nyberg F, Gerber M, Liu M. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015, 8:255-73. 10.1177\/1756285615602832","journal-title":"Ther Adv Neurol Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-233552","article-title":"Progressive multifocal leukoencephalopathy following five lines of therapy and three autologous bone marrow transplants for multiple myeloma","volume":"13","author":"Knight K","year":"2020","unstructured":"Knight K, Chien S, Koutsavlis I, Campbell V. Progressive multifocal leukoencephalopathy following five lines of therapy and three autologous bone marrow transplants for multiple myeloma. BMJ Case Rep. 2020, 13:10.1136\/bcr-2019-233552","journal-title":"BMJ Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2018.01.002","article-title":"T cell deficiencies as a common risk factor for drug associated progressive multifocal leukoencephalopathy","volume":"223","author":"Pavlovic D","year":"2018","unstructured":"Pavlovic D, Patel MA, Patera AC, Peterson I. T cell deficiencies as a common risk factor for drug associated progressive multifocal leukoencephalopathy. Immunobiology. 2018, 223:508-17. 10.1016\/j.imbio.2018.01.002","journal-title":"Immunobiology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-429415","article-title":"Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6","volume":"121","author":"Witzens-Harig M","year":"2013","unstructured":"Witzens-Harig M, Hose D, J\u00fcnger S, et al.. Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6. Blood. 2013, 121:4493-503. 10.1182\/blood-2012-05-429415","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s0145-2126(01)00192-8","article-title":"Relationship between CD4(+)\/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16","volume":"26","author":"Koike M","year":"2002","unstructured":"Koike M, Sekigawa I, Okada M, et al.. Relationship between CD4(+)\/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16. Leuk Res. 2002, 26:705-11. 10.1016\/s0145-2126(01)00192-8","journal-title":"Leuk Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235759","article-title":"Immunomodulatory agents for multiple myeloma","volume":"14","author":"Mina\u0159\u00edk J","year":"2022","unstructured":"Mina\u0159\u00edk J, \u0160ev\u010d\u00edkov\u00e1 S. Immunomodulatory agents for multiple myeloma. Cancers (Basel). 2022, 14:10.3390\/cancers14235759","journal-title":"Cancers (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.728597","article-title":"Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma","volume":"54","author":"Zhu YX","year":"2013","unstructured":"Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013, 54:683-7. 10.3109\/10428194.2012.728597","journal-title":"Leuk Lymphoma"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu L","year":"2008","unstructured":"Wu L, Adams M, Carter T, et al.. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008, 14:4650-7. 10.1158\/1078-0432.CCR-07-4405","journal-title":"Clin Cancer Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson KR","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA, et al.. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009, 113:4834-40. 10.1182\/blood-2008-10-186999","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0098","article-title":"Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy","volume":"15","author":"Tuccori M","year":"2010","unstructured":"Tuccori M, Focosi D, Blandizzi C, et al.. Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist. 2010, 15:1214-9. 10.1634\/theoncologist.2010-0098","journal-title":"Oncologist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/296811-pardon-my-language-the-curious-case-of-a-bloody-sandwich-and-the-john-cunningham-virus-reactivation-in-the-era-of-immunomodulatory-drugs","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T16:11:19Z","timestamp":1729786279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/296811-pardon-my-language-the-curious-case-of-a-bloody-sandwich-and-the-john-cunningham-virus-reactivation-in-the-era-of-immunomodulatory-drugs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.72306","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,24]]}}}